Company Overview
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $23.34M (+28.7% YoY); net profit $-101.27M.
- Trailing 12 Months Year-on-year growth — revenue -77.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -10.70% |
| 1 Year: | -77.20% |
Stock Price Performance
| 1 Year: | -97.51% |
| 6 Months: | -90.04% |
| 3 Months: | -78.33% |
| 1 Month: | -56.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.03 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -10.7% CAGR over 5 years.
- Trading 99.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MEDS DataMEDS AI, Inc. PHARMA | 0.87 | -0.02 | $2.78M | 0.00% | - | - | -10.70% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 10.86M | 7.79M | 3.01M | 1.67M | 1.56M |
| Cost of Revenue | 10.17M | 7.29M | 2.78M | 9.53M | 1.39M |
| Gross Profit | 692.64K | 505.75K | 231.01K | -7.86M | 170.22K |
| Operating Expenses | 32.04M | 6.01M | 31.78M | 4.94M | 6.19M |
| Operating Income | -31.35M | -5.50M | -31.55M | -12.80M | -6.02M |
| EBITDA | -30.53M | -4.69M | -32.09M | -26.17M | -5.31M |
| Interest Expense | 1.09M | 1.18M | 1.43M | 875.72K | 2.07M |
| Pretax Income | -32.43M | -6.67M | -34.32M | -27.85M | -7.74M |
| Tax Provision | 0 | 0 | 0 | 0 | 0 |
| Net Income | -32.43M | -6.67M | -34.32M | -27.85M | -7.74M |
| Diluted EPS | -31.00 | -5.50 | -23.00 | - | -3.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 32.78M | 0 | 18.13M | 23.34M |
| Cost of Revenue | 27.03M | 0 | 16.36M | 29.76M |
| Gross Profit | 5.75M | 0 | 1.77M | -6.43M |
| Operating Expenses | 9.17M | 2.88M | 7.91M | 74.77M |
| Operating Income | -3.42M | -2.88M | -6.15M | -81.19M |
| EBITDA | -369.03K | -2.88M | -4.91M | -93.48M |
| Interest Expense | 287.18K | 15.08K | 831.47K | 4.58M |
| Pretax Income | -2.74M | -2.90M | -6.86M | -101.27M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -2.74M | -2.90M | -6.86M | -101.27M |
| Diluted EPS | -2.90 | -3.00 | -7.50 | -71.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 0 | 338.36K | 57.33M | 30.46M |
| Current Assets | 0 | 338.36K | 15.17M | 2.82M |
| Cash & Equivalents | 0 | 1.36K | 1.03M | 42.57K |
| Inventory | - | 0 | 9.52M | 1.64M |
| Receivables | - | 0 | 2.72M | 1.14M |
| Total Liabilities | 5.25K | 3.24M | 50.60M | 42.91M |
| Current Liabilities | 5.25K | 2.89M | 38.05M | 29.78M |
| Long Term Debt | - | 350.00K | 11.46M | 12.60M |
| Total Debt | - | 350.00K | 25.11M | 24.77M |
| Total Equity | -5.25K | -2.90M | 6.73M | -12.45M |
| Shares Outstanding | 1.04M | 1.04M | 1.04M | 2.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 0 | -349.14K | -1.22M | -10.86M |
| Investing Cash Flow | - | 0 | 469.07K | -881.53K |
| Financing Cash Flow | 0 | 350.50K | 1.78M | 10.75M |
| Capital Expenditure | - | - | -377.29K | -881.53K |
| Free Cash Flow | 0 | -349.14K | -1.60M | -11.74M |
| Net Change in Cash | - | 1.36K | 1.03M | -985.76K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 17.5% | - | 9.7% | -27.5% |
| Operating Margin % | -10.4% | - | -33.9% | -347.9% |
| Net Margin % | -8.4% | - | -37.8% | -433.9% |
| ROE % | 52,262.9% | 99.8% | -101.8% | 813.6% |
| ROCE % | 65,194.8% | 112.9% | -31.9% | -11,952.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.64% | 20.53K | $77.20K |
| 2 | Geode Capital Management, LLC | 0.39% | 12.47K | $46.88K |
| 3 | Vanguard Capital Management LLC | 0.35% | 11.09K | $41.68K |
| 4 | Vanguard Fiduciary Trust Co | 0.19% | 6.19K | $23.28K |
| 5 | Tower Research Capital LLC (TRC) | 0.02% | 678 | $2.55K |
| 6 | Barclays Plc | 0.02% | 723 | $2.72K |
| 7 | Fortitude Family Office, LLC | - | 118 | $443 |
| 8 | Global Retirement Partners, LLC | - | 2 | $7 |
| 9 | Danske Bank A/s | - | 1 | $3 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MEDS
DataMeds AI (MEDS) details dilution risk from May 2026 notes deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQMWhVU29Obk9RVXBEUHlPcExLQ0ZDNnZjZkZiYnRJWE1wYXJvMVdZYlREWGdmcjhnLUpvYWUyTnBHNG5SSzJoNW9OSzZQekdGQlVFemI4QlV3dGtVT0RZVXVxVzJKa2dSUEdzWHVhTVFvdnpKaGlvWms2a3RlR29hWkp1TkRpY3dZckFSbn…
MEDS Stock Draws Traders As Corexa Pharmacy Revenue Holds Strong - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5INVRKMGlZMndNdnF0ejY2UHBla2loSFRoN2s0NmhDSk5mM0sydUtYVUZ4UXJoN05HOERDNTFabVVuQlhlSk55eVZnUElYYjhVaFNVX0pFMERxWFF2OXQ3TzJJbjRQWXRLNWZQZzVWZVJYR1dkZnc?oc=5" target="_blank">MEDS Sto…
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOZUt2ZnkwcHpSRUFQV1plMEZfVjVXcVo1RDlaMWx6RnNvc0tqSGc2SFZOOVV5Tjg4RmRZWVZTM0R0OWExbUZnY3VjVkVYVU5lRFN4ajhZNjZLaVEwSHhZQ1N6Y1U3eWFja0JMWDNhdUl2eFBvdTVkQlhDYWI0d1dYMC1BUVYwcWJUUEtMRy…
DataMEDS AI, Inc. (NASDAQ: MEDS) Share Price, MEDS Stock News, MEDS Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9OT3IyLXR2YzFPMGZCMFhRaGp3NWtObnFhZkxDOExETVctdkpWcDFqZ3N0bU9mUDlBMGkxaktUWFdISTdpQ3BUczhucnlrWGQ0Z0NiOUFn?oc=5" target="_blank">DataMEDS AI, Inc. (NASDAQ: MEDS) Share Price, MEDS …
Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs - KFF Health News
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNX2diMmlJNnN1cFl0Mm1fZXhKUHllMGtVZW8xQjU2ZzBKQk16MTJsZURCTFRQTnV6Z3VsLUhrcTdVUDl4eHUwdXAwb1NZcmRlamJ2cC00OTcyTm9QREFuY3BHVzBOaVNfUG5VdTJ3S1oyR1VJQXpwd3ZFSmFTcXJOSllsdy1GS0U4RWFTOU…
DataMEDS AI Officially Begins Trading Under Stock Symbol 'MEDS' on the NASDAQ Capital Markets - ACCESS Newswire
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNVGdVMmlLWFVKdE1ZcVhIOGVyN1V3SlkwbGZEYXpnRHV4OU5qQVVMMzNRZTB3S3pGbGpqMDZWclh0YmIzb2ZPX01TcXpaRWtjd3hxWWRmRVNoS1VtbHJXbmR3NElEQUsydXliZ1JOeU5wZUVqS0xzbkRlV0ZmTmlhaW1pcGgzRFZGS0Q4UE…
MEDS — Frequently Asked Questions
What is the current share price of DataMEDS AI, Inc. (MEDS)?
As of 2026-09-19 21:16 PDT, DataMEDS AI, Inc. (MEDS) trades at $0.87 on NasdaqCM. Its 52-week range is $0.87 to $86.50.
What is the market capitalisation of MEDS?
DataMEDS AI, Inc. (MEDS) has a market capitalisation of $2.78M on NasdaqCM.
What is the P/E ratio of MEDS?
MEDS trades at a trailing price-to-earnings (P/E) ratio of -0.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.55.
Is MEDS a good stock to buy?
This page provides a data-driven analysis of DataMEDS AI, Inc. (MEDS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.